Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk - (DGNews)
    Extended-Release Paliperidone Resolves Schizophrenia Exacerbations Faster Than Quetiapine: Presented at CINP - (DGDispatch)
    Risperidone With Standard Therapy Reduces Relapses of Bipolar Episode Regardless of Episode Type: Presented at CINP - (DGDispatch)
    General Practitioners Prescribing Potentially Inappropriate Psychotropic Medications to Older Patients With Generalised Anxiety: Presented at CINP - (DGDispatch)
    Intranasal Desmopressin Loses Indication for Primary Nocturnal Enuresis in Canada - (DGNews)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Hepatitis C: Treatment Strategies to Maximize Outcomes
      Delirium in the Elderly: Medications, Causes, and Treatment
      New Drugs of 2007
      Motion Sickness: Calming the Waves of Upset
      Parkinson's Disease: Quality Assessment and Improvement of Care

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Successful Management of Acute Thromboembolic Disease Complicated with Heparin Induced Thrombocytopenia Type II (HIT II): A Case Series
        Decrease in Tobacco Consumption After Treatment with Topiramate and Aripiprazole
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Successful Treatment of Kasabach-Merritt Syndrome with Vincristine and Surgery: A Case Report and Review of Literature
        Tender Nodules on the Palms and Soles After Chemotherapy

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Rabeprazole/ Levofloxacin/Rifabutin Therapy Equally Effective as Quadruple Therapy in Second-Line Treatment of Helicobacter Pylori

        A DGReview of :"Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection"
        Alimentary Pharmacology & Therapeutics

        03/18/2003
        By David Ball


        Rabeprazole, levofloxacin and rifabutin-based triple therapy is just as effective as quadruple therapy, as second-line treatment for Helicobacter pylori infection, say Chinese researchers.

        The researchers, led by W.M.Wong and colleagues at the Department of Medicine, University of Hong Kong, Queen Mary Hospital, tested the efficacy of the two regimens in 109 patients who had all failed H. pylori eradication earlier. The patients were randomised into two groups.

        The triple therapy group received rabeprazole, 20 mg twice daily; rifabutin, 300 mg once daily; and levofloxacin, 500 mg once daily, for seven days.

        Those in the quadruple therapy group were given rabeprazole, 20 mg twice daily; metronidazole, 400 mg three times daily; bismuth subcitrate, 120 mg four times a day; and tetracycline, 500 mg four times daily, for seven days.

        Endoscopy and culture were performed before treatment.

        Significantly higher resistance rates were found in subjects with previous exposure compared with those with no previous exposure: clarithromycin, 79 vs. 21% ( P < 0.001) and metronidazole, 89 vs. 40% (P < 0.001).

        In the triple therapy group, the intention-to-treat and per protocol eradication rates were 91%/91% and for the quadruple therapy subjects they were 91%/92%.

        The eradication rate for patients in the triple therapy group with double resistance to metronidazole and clarithromycin was 85%, 17 of 20 subjects.

        In the quadruple therapy group the eradication rate for those with double resistance to metronidazole and clarithromycin was 87%,13 of 15 subjects.

        Both regimens showed a compliance rate greater than 95 %.
        Aliment Pharmacol Ther 2003 Feb;17:4:553-60. "Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send